Class / Patent application number | Description | Number of patent applications / Date published |
514110100 | Somatostatin or derivative | 37 |
20100323964 | NEW NON-SELECTIVE SOMATOSTATIN ANALOGUES - The present invention relates to a new class of cyclopeptides of formula ( | 12-23-2010 |
20110124563 | PHARMACEUTICAL COMPOSITION WITH PROLONGED RELEASE OF SOMATOSTATIN OR AN ANALOGUE THEREOF - The invention relates to a sustained release pharmaceutical composition of somatostatin, or an analog of somatostatin, for its use in treating and/or preventing diarrhea and its use in preparing a medicinal product for treating and/or preventing diarrhea. | 05-26-2011 |
20110178013 | NOVEL OCTAPEPTIDE COMPOUNDS DERIVED FROM SOMATOSTATIN AND THE THERAPEUTIC USE THEREOF - The present invention relates to novel octapeptide compounds of general formula (I): H-2-Nal | 07-21-2011 |
20110183905 | PHARMACEUTICAL COMPOSITIONS - A liquid pharmaceutical composition comprising a biodegradable polymer, polyethylene glycol having a molecular weight of less than 600 Daltons, a pharmaceutically active agent and less than 0.5% of an biologically acceptable organic solvent. | 07-28-2011 |
20110257096 | COMPOSITIONS FOR DRUG ADMINISTRATION - The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms. In various aspects, the invention provides compositions and methods for oral delivery of peptides containing non-naturally occurring structures including D-amino acids and/or chain cyclization. | 10-20-2011 |
20110269683 | RECEPTOR(SSTR2)-SELECTIVE SOMATOSTATIN ANTAGONISTS - SRIF peptide antagonists, which are selective for SSTR2 in contrast to the other cloned SRIF receptors and which bind with high affinity to the cloned human receptor SSTR2 but do not activate the receptor, have many useful functions. Because they do not bind with significant affinity to SSTR1, SSTR3, SSTR4 or SSTR5, their administration avoids potential undesirable side effects. By incorporating radioiodine or the like in these SSTR2-selective SRIF antagonists, a labeled compound useful in drug-screening methods is provided. Alternatively, for use in therapy, highly radioactive moieties can be N-terminally coupled, complexed or chelated thereto. Because they block the receptor function, they can be used therapeutically to block certain physiological effects which SSTR2 mediates. | 11-03-2011 |
20110319329 | USE OF SOMATOSTATIN ANALOGS IN CLUSTER HEADACHE - The present invention relates to the use of a Somatostatin (SRIF) analog which has a high binding affinity to human SSTR1,2,3,5, or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for the treatment of cluster headache. | 12-29-2011 |
20120083444 | Emulsion Method For Preparing Low Residual Solvent Microparticles - The method disclosed herein comprises using a non-polar alkane in the continuous phase of an emulsion process to aid in the removal of dispersed phase solvent from the microparticles. The microparticles can further be subjected to a post-production treatment process, involving a non-polar alkane suspension and a rinse, to further reduce residual dispersed phase solvent levels. | 04-05-2012 |
20120122781 | PEPTIDE LIGANDS OF SOMATOSTATIN RECEPTORS - Peptide derivatives, their stereoisomers, mixtures thereof and/or their pharmaceutically acceptable salts, a method of obtaining them, pharmaceutical compositions containing them and the use thereof for the treatment, prevention and/or diagnosis of those conditions, disorders and/or pathologies in which the sstr1, sstr2, sstr3, sstr4 and/or sstr5 somatostatin receptors are expressed. | 05-17-2012 |
20120277153 | TREATING LIVER DISEASES - This document provides methods and materials related to treating liver conditions. For example, the methods and materials relating to the use of cAMP inhibitors to treat liver conditions are provided. | 11-01-2012 |
20120302500 | USE OF SOMATOSTATIN ANALOGS IN MENINGIOMA - The present invention relates to the use of a Somatostatin (SRIF) analog which has a high binding affinity to human SSTR1,2,3,5, or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for the treatment of meningioma. | 11-29-2012 |
20130079282 | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR THE SUSTAINED RELEASE OF SOMATOSTATIN ANALOGS - The invention relates to a process for the preparation of injectable pharmaceutical compositions for the sustained release of somatostatin analogues and to pharmaceutical compositions prepared according to the process. In a preferred aspect the process comprises the steps of combining lanreotide acetate and acetic acid, lyophilizing the resulting mixture only once, and hydrating the lyophilizate. Acetic acid may be added to a desired pH during the final step of the process. | 03-28-2013 |
20130085105 | Transdermal Administration Of Peptides - The present invention relates to a method of increasing the bioavailability of a peptide. The method includes altering the lipophilicity of a peptide by the creation of fatty acid peptide salts of the peptide. The fatty acid peptide salts exhibit increased transdermal and transmucosal permeability. | 04-04-2013 |
20130116178 | PHARMACEUTICAL COMPOSITIONS COMPRISING POLYETHYLENE GLYCOL HAVING A MOLECULAR WEIGHT OF LESS THAN 600 DALTONS - A liquid pharmaceutical composition comprising a biodegradable polymer, polyethylene glycol having a molecular weight of less than 600 Daltons, a pharmaceutically active agent and less than 0.5% of an biologically acceptable organic solvent. | 05-09-2013 |
20130210728 | TOPICAL OPHTHALMIC PEPTIDE FORMULATION - A topical ophthalmic formulation of peptides and their use for the treatment and/or local prevention of ocular diseases, preferably posterior segment eye diseases. | 08-15-2013 |
20130237480 | COMBINATIONS OF SOMATOSTATIN-ANALOGS WITH DIFFERENT SELECTIVITY FOR HUMAN SOMATOSTATIN RECEPTOR SUBTYPES - The present invention relates to a combination of two or more Somatostatin (SRIF) peptidomimetics (also referred to as Somatostatin- or SRIF-analogs) which have different selectivity for the five human somatostatin receptor subtypes, the use of such combination in the treatment of a disease mediated by activation of somatostatin receptors, and to pharmaceutical compositions comprising such a combination. | 09-12-2013 |
20130252892 | NOVEL OCTAPEPTIDE COMPOUNDS AND THERAPEUTIC USE THEREOF - The present invention relates to novel octapeptide compounds of general formula (I), | 09-26-2013 |
20130261057 | METHODS FOR THERAPEUTIC TREATMENT OF BENIGN PROSTATIC HYPERTROPHY (BPH) - Therapeutic methods for treatment of benign prostatic hypertrophy by inhibition of the activity of insulin-like growth factor-I (IGF-I) are described herein. Methods encompass the use of IGF-I antagonists, as well as the use of compounds that lower the effective level of IGF-I or interfere with post receptor effects of IGF-I action in the prostate. | 10-03-2013 |
20130303453 | OCTREOTIDE INJECTION - The present invention provides a sterile solution comprising octreotide acetate in a pharmaceutically acceptable vehicle, wherein solution is present as a reservoir in a multiple dose pen injection device, the device being adapted to subcutaneously inject a portion of the said reservoir in multiple daily doses and further being adapted to provide multiple portions of the said solution, while the reservoir remains sterile. | 11-14-2013 |
20130324467 | NEUROPEPTIDE ANALOGS, COMPOSITIONS, AND METHODS FOR TREATING PAIN - Neuropeptide analogs and compositions including neuropeptide analogs are described herein. Also provided are methods of producing and using the neuropeptide analogs and compositions including one or more neuropeptide analogs. | 12-05-2013 |
20140031288 | NOVEL COMPOSITION FOR TUMOR GROWTH CONTROL - The invention describes a pharmaceutical composition comprising at least compound selected from the group of demethylating agents and HDAC inhibitors and at least one somatostatin analog or dopamine agonist for the treatment of a tumor which expresses a somatostatin and/or dopamine receptor. | 01-30-2014 |
20140045752 | MULTICOMPONENT COMPOSITIONS AND THE USES - Multicomponent compositions and methods of use thereof are disclosed herein. Some embodiments of the present invention include multicomponent compositions comprising a first component and a second component, where the first component comprises a notch influencing molecule and the second component comprises a GPCR targeted molecule. Kits comprising the multicomponent composition are also disclosed. Methods for providing the multicomponent composition to one or more cells are additionally provided. Further embodiments include methods of using the multicomponent composition such as, for example, methods of administering the multicomponent composition and method of treating organisms (such as mammals) using the multicomponent composition. | 02-13-2014 |
20140171368 | POLYANION NANOCOMPLEXES FOR THERAPEUTIC APPLICATIONS - The subject-matter of the present invention are nanocomplexes of polyanions and cationic peptides which are, e.g., suitable for the transport of drugs into cells and their controlled release in the organism, as well as a complex material in which the nanocomplexes are bonded to a biologically active unit for the selective recognition of tissues, cells or organelles. | 06-19-2014 |
20140296144 | PROCESS FOR THE PREPARATION OF OCTREOTIDE ACETATE - The present invention relates to an improved process for large scale production of Octreotide acetate. The invention also relates to pharmaceutical composition of octreotide acetate. | 10-02-2014 |
20140329749 | ROBUST CONTROLLED-RELEASE PEPTIDE FORMULATIONS - The present invention relates to compositions forming a low viscosity mixture of: a. 25-55 wt. % of at least one diacyl glycerol and/or at least one tocopherol; b. 25-55 wt. % of at least one phospholipid component comprising phospholipids having i. polar head groups comprising more than 50% phosphatidyl ethanolamine, and ii. two acyl chains each independently having 16 to 20 carbons wherein at least one acyl chain has at least one unsaturation in the carbon chain, and there are no more than four unsaturations over two carbon chains; c. 5-25 wt. % of at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein 0.1-10 wt. % of at least one peptide active agent comprising at least one somatostatin receptor agonist is dissolved or dispersed in the low viscosity mixture; and wherein the pre-formulation forms, or is capable of forming, at least one non-lamellar liquid crystalline phase structure upon contact with an aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled administration devices and kits containing the formulations. | 11-06-2014 |
20140336116 | Glycosylated Polypeptide and Drug Composition Containing Said Polypeptide - [Problem] To provide a glycosylated polypeptide having an affinity to somatostatin receptors, and, compared to somatostatins, having improved in-blood stability. [Solution] The glycosylated polypeptide is characterized by at least one amino acid in a somatostatin or an analog thereof being replaced with a glycosylated amino acid. | 11-13-2014 |
20140349937 | METHODS FOR TREATING BENIGN PROSTATIC HYPERTROPHY (BPH) - Therapeutic methods for treating a subject with benign prostatic hypertrophy by inhibition of the activity of insulin-like growth factor-I (IGF-I) to reduce the amount of prostatic hyperplastic tissue in the subject are described herein. | 11-27-2014 |
20150038414 | Organic Compounds - A pharmacutical composition for parenteral administration of a somatostatin analogue salt of aspartate, e.g. mono- or diaspartate, lactate, succinate, e.g. mono- or disuccinate, acetate, glutamate, e.g. mono- or diglutamate or citrate and water forming a gelling depot system after injection in contact with the body fluid. | 02-05-2015 |
20150087588 | COMBINATION OF SOMATOSTATIN-ANALOGS WITH 11BETA-HYDROXYLASE INHIBITORS - The present invention relates to a combination which comprises (a) a somatostatin analogue and (b) a 11beta-hydroxylase inhibitor; each in free form or in the form of a pharmaceutical acceptable salt thereof; the use of such a combination for the preparation of a medicament for the treatment of diseases associated with increased stress hormone levels; a commercial package or product comprising such a combination; and to a method of treatment of a warm-blooded animal, especially a human. | 03-26-2015 |
20150141338 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE - An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug. | 05-21-2015 |
20150148294 | Neuroendocrine Tumor Treatment - A method for treating endocrine tumors by administration of an mTOR inhibitor, optionally in combination with another drug. | 05-28-2015 |
20150290330 | Somatostatin-Dopamine Chimeric Analogs - The present invention relates to novel somatostatin-dopamine chimeric analogs and their therapeutic uses for the inhibition, prevention, and/or treatment of neoplasia, neuroendocrine tumors, Cushing's disease/syndrome, and other conditions. | 10-15-2015 |
20150366973 | PEPTIDE SLOW-RELEASE FORMULATIONS - Disclosed herein are compositions for the delayed delivery of peptide active agents, including compositions comprising; i) a salt of a peptide active agent comprising at least one positively charged peptide ion and at least one negatively charged counter-ion selected from a halide ion, a chloride and a bromide ion; and ii) a sustained-release delivery vehicle. | 12-24-2015 |
20160051624 | ANTIBACTERIAL COMPOSITIONS FOR DRUG ADMINISTRATION - Non-toxic aqueous compositions are provided having antibacterial activity. Specifically, the invention provides aqueous alkyl glycoside or saccharide alkyl ester compositions which meet the antimicrobial effectiveness test criteria set forth in USP 31 <51> in preventing growth of specified bacteria and fungi. | 02-25-2016 |
20160058841 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE - An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug. | 03-03-2016 |
20160089417 | TREATING LIVER DISEASES - This document provides methods and materials related to treating liver conditions. For example, the methods and materials relating to the use of cAMP inhibitors to treat liver conditions are provided. | 03-31-2016 |
20160151447 | PHARMACEUTICAL COMPOSITION FOR A SUSTAINED RELEASE OF LANREOTIDE | 06-02-2016 |